The aim of this study is to see if there is an association between geriatric screening and outcomes. This could lead to a prediction of clinical outcomes in older patients visiting the hospital, using a mix of routine clinical parameters and…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Veroudering, invasieve therapie en de uitkomsten
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study end points are:
The following data will be collected from the medical record after the
treatment of the patient is finished:
i) duration of admittance
ii) days on intensive care or medium care
iii) clinical diagnosis of delirium during hospitalization
iv) complications during admittance (infections, falls)
v) unplanned hospital admittance
After a Follow-up of 6 and 12 months after procedure we will collect the
following data by a telephone call:
i) Mortality will be followed through the registry of the municipality (in
Dutch: Gemeentelijke Basis Administratie).
ii) Functional decline by Katz-ADL
iii) Quality of life will be assessed using EuroQOL-5D.
iv) Living arrangement (independent, institutionalized, hospitalized) and level
of support (number of days home-care)
Secondary outcome
not applicable
Background summary
Aging is accompanied by an increased vulnerability with a consequently higher
risk of disease and death. However, older patients are characterized by a high
degree of heterogeneity and calendar age alone is a poor marker of individual
vulnerability or vitality. A solid measurement of this vitality is especially
essential in decision-making in older patients needing invasive treatments like
surgery, radiation or chemotherapy.
Conventional geriatric assessment of physical, psychological and social
function likely yields valuable predictors, but validated predictors have not
been firmly established in the clinical setting. Furthermore, novel makers of
biological age and vitality have been identified in various studies (serum
biomarkers and measurement of physical activity using accelerometers) and hold
great promise, but have sparsely been tested in in the clinical setting.
The Department of Gerontology and Geriatrics of the LUMC has implanted several
care pathways on different departments to improve the care for older
patients.The geriatric screening is done on those departments and patients are
only referred to geriatric doctors in case of abnormalities.
The current study is using the baseline parameters derived from the routine
clinical work-up. After a follow-up of 6 and 12 months after procedure we will
collect data by reaching out to the patients. Additionally, for this study a
blood sample will be collected in context of a WMO-protocol, DNA isloation and
for storage. This will be used for future research.
The working hypothesis will be that vulnerable older patients will have worse
outcomes in compare with their less vulnerable comparable peers. Besides that
we think that geriatric measurements can be an important predictor for the
outcomes of treatment.
Study objective
The aim of this study is to see if there is an association between geriatric
screening and outcomes. This could lead to a prediction of clinical outcomes in
older patients visiting the hospital, using a mix of routine clinical
parameters and biomarker-derived measurements.
Study design
For the present study, the data are collected as part of routine clinical
practice and additionally 1) follow-up data will be collected from the medical
record regarding the treatment and 6 and 12 months after contacting the
patients, 2) baseline blood samples will collected in context of a WMO-protocol
and be stored in a biobank for later analysis. 3) a selection of patients will
be asked to participate in the resilience study, for which they will carry a
wrist band for 12 weeks that measures their physical capacity.
Study burden and risks
After the patient gives informed consent, the extra burden in this study will
be drawing of one extra blood sample for purposes of the WMO-protoco inlcuding
DNA isolationl and for storage in the *biobank* (mostly in combination with
routing clinical blood drawing) and twice contact by telephone, once after 6
months and once after 12 months. The maximum time spent on the extra burden is
one hour per participant for the total study.
All other baseline and follow-up data can be collected from the medical record
and Municipality Records ("gemeentelijke basis-administratie").
Albinusdreef 2
Leiden 2300 RC
NL
Albinusdreef 2
Leiden 2300 RC
NL
Listed location countries
Age
Inclusion criteria
1. Aged 70 years or older at day of presentation or younger than 70 with
indication for frailty
2. Indication intention to treat for:
- Malign process in which a treatment (operation, chemotherapy or radiotherapy)
is considered
- Vascular disease in which a treatment (operation) is considered
- Benign processes in which a treatment (operation, chemotherapy or
radiotherapy) is considered
- Referral to the outpatient department of gerontology and geriatrics for
(neuropsychological) screening or any other reason, subjects older than 70
years could also be included when they are considered vulnerable
Exclusion criteria
1. Participant not willing to provide informed consent
2. Participant not able to provide informed consent and no proxy available
Design
Recruitment
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL53575.058.15 |
| OMON | NL-OMON28769 |